RxDoctor Payments Data

Lorie Dwyer, NP

Family · Fort Wayne, INNPI 1538479845

Payments from drug & device makers

$12,716in general payments, 2019–2025

Across 890 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • Lilly USA, LLC$893
  • Novo Nordisk$845
  • Pfizer$738
  • GSK$572
  • plus $6K from 43 others

What the payments were for

  • Food & beverage$12,60899%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,716 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$37,264
Medicare patients
111
Services billed
3,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide47$62,976
FarxigaDapagliflozin Propanediol25$39,009
OzempicSemaglutide36$36,277
EliquisApixaban30$35,996
JardianceEmpagliflozin21$33,718
MounjaroTirzepatide31$32,718
Soliqua 100-33Insulin Glargine/Lixisenatide24$24,281
RybelsusSemaglutide11$22,528
GemtesaVibegron16$22,294
VascepaIcosapent Ethyl19$19,633
TradjentaLinagliptin12$18,956
MyrbetriqMirabegron16$15,678
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$13,229
BelsomraSuvorexant16$12,269
NexlizetBempedoic Acid/Ezetimibe11$12,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$893$95,69478 claims
Novo NordiskOzempic, Rybelsus$845$58,80447 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$340$57,90644 claims
AstraZenecaFarxiga$1,380$39,00925 claims
PfizerEliquis$738$35,99630 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$242$24,28124 claims
Sumitomo Pharma America, Inc.Gemtesa$306$22,29416 claims
MerckBelsomra, Januvia$145$21,76030 claims
Astellas Pharma US IncMyrbetriq$301$15,67816 claims
Esperion Therapeutics, Inc.Nexlizet$78$12,23111 claims
GSKTrelegy Ellipta$572$11,72412 claims
AbbVieSynthroid, Armour Thyroid$2,575$4,30349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →